Confidence in a New COVID-19 Focus
At Algernon we have a growing confidence in the new therapeutic potential of NP-120 (Ifenprodil):
- As a result of the strong data from our own Ifenprodil studies, along with that of the independent studies, we decided to expand our Ifenprodil clinical program to include acute lung injury (ALI) – which is a specific form of injury with diverse causes including influenza related pneumonia – and COVID-19.
- With an overall mortality rate between 3% to 4% (based on WHO data), COVID-19 infected patients can also experience profound pulmonary complications including lung infiltrates, opacification, and risk of adult respiratory distress syndrome. Some patients who recover may also suffer a reduction of lung capacity from 20% to 30% as well. Beyond systemic steroid therapy, clinicians have few agents with which to treat these patients.
- Ifenprodil may offer a new and efficacious treatment option that limits inflammatory infiltrates and the resulting fibrotic responses, as suggested in its earlier animal model studies.